DEFR14A: OPKO Health Amends Proxy Statement for XBRL Tagging in Pay Versus Performance Disclosure

OPKO Health files an amendment to its proxy statement solely to include Inline XBRL tagging in the Pay Versus Performance section, with no other changes to the document.

Summary

• OPKO Health, Inc. amended its proxy statement filed on February 29, 2024, to include Inline XBRL tagging in the Pay Versus Performance section.
• The amendment does not change any other part of the proxy statement.
• The Pay Versus Performance section includes a table showing total compensation for Named Executive Officers (NEOs) for fiscal years 2023, 2022, 2021, and 2020.
• The table compares Summary Compensation Table (SCT) total pay to Compensation Actually Paid (CAP) for the CEO and other NEOs.
• It also includes the company's Total Shareholder Return (TSR), the TSR of the Nasdaq Biotechnology Index, net income, and revenue over the same period.
• For 2023, the CEO's SCT total pay was $2,277,200 and CAP was $2,173,575, while the average SCT total pay for other NEOs was $2,031,950 and average CAP was $1,925,029.
• The value of an initial $100 investment in OPKO Health in 2020 would be $102.72 in 2023, compared to $118.87 for the Nasdaq Biotechnology Index.
• The company's net income was a loss of $188,863 in 2023, and revenue was $863,495.
• The increase in CAP for 2023 was primarily due to a stock option grant to the CEO and NEOs.
• The company uses adjusted operating income, revenue, and relative TSR as key financial performance measures for setting pay-for-performance compensation.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, with a neutral tone. The amendment addresses a technical requirement (XBRL tagging) and presents data on executive compensation and company performance. While there are some negative aspects (net loss, TSR underperformance), the overall sentiment is balanced.

Positives

• The company's TSR improved in 2023 compared to previous years.
• The company reported a smaller decline in net income in 2023.
• The increase in CAP for 2023 was driven primarily by a stock option grant to the CEO and NEOs, incentivizing performance.

Negatives

• The company reported a net loss of $188,863 in 2023.
• The company's TSR underperformed the Nasdaq Biotechnology Index in 2023.

Risks

• The Pay Versus Performance disclosure may not align with the company's view of the relationship between performance and executive compensation.
• The company may determine a different financial performance measure to be the most important in future years, which could impact executive compensation.

Future Outlook

The company may determine a different financial performance measure to be the most important in future years.

Management Comments

• We believe our discussion in the Compensation Discussion and Analysis properly outlines how we view our executive compensation structure and how that aligns with the Company's performance and objectives.
• We believe the CAP in each of the years reported above aligns with the performance metrics presented.

Industry Context

The document compares OPKO Health's TSR to the Nasdaq Biotechnology Index, providing context within the biotechnology industry.

Comparison to Industry Standards

• The document compares OPKO Health's TSR to the Nasdaq Biotechnology Index, which serves as a peer group benchmark.
• The document does not provide specific comparisons to individual companies, but the Nasdaq Biotechnology Index represents a broad range of companies in the biotechnology sector.

Stakeholder Impact

• The Pay Versus Performance disclosure provides transparency to shareholders regarding executive compensation and its relationship to company performance.
• The information may influence shareholder voting decisions on executive compensation matters.

Key Dates

Keywords

Pay Versus Performance, Executive Compensation, Proxy Statement, XBRL Tagging, Total Shareholder Return, Net Income, Revenue, OPKO Health, NEOs, CEO